Fda clears aviclear® as a long-term treatment for mild to severe acne

Brisbane, calif.--(business wire)--cutera, inc. (nasdaq: cutr) a global leader in aesthetic and dermatology solutions, today announces a new u.s. food and drug administration clearance of aviclear as a long-term treatment for mild to severe inflammatory acne vulgaris. this is the first acne therapy to claim long term effectiveness for mild, moderate and severe acne. aviclear initially received fda clearance in march 2022 following an extensive clinical trial. now after months of clinical data e.
CUTR Ratings Summary
CUTR Quant Ranking